ONCE – FDA schedules October 12 Cellular, Tissue, and Gene Therapies Advisory Committee meeting to discuss and make recommendations on the safety and effectiveness of biologics license application for voretigene neparvovec.
BLT Price at posting:
12.5¢ Sentiment: Buy Disclosure: Held